Arog Pharmaceuticals, LLC is developing CRENOLANIB, an orally bioavailable, mutant specific type I inhibitor of receptor kinases FLT3, PDGFRa, and PDGFRb. Crenolanib is currently in phase III development in AML and GIST.
Contact this Exhibitor